淋巴瘤化疗后粒细胞减少预防中聚乙二醇化重组人粒细胞集落刺激因子的应用观察
|
摘要
目的:探讨聚乙二醇化重组人粒细胞集落刺激因子对淋巴瘤化疗后粒细胞减少的预防作用。方法:选取60例淋巴瘤化疗患者进行分析,将其随机分组,观察组给予聚乙二醇化重组人粒细胞集落刺激因子,对照组给予重组人粒细胞集落刺激因子,每组各30例。结果:治疗后,两组患者的生存质量计分、KPS评分均显著优于治疗前(P<0.05),且观察组显著优于对照组(P<0.05)。观察组平均最低ANC值为(5.31±0.51)×109/L,ANC<2.0×10~9/L持续时间为(3.15±1.02)d,对照组平均最低ANC值为(5.52±0.48)×109/L,ANC<2.0×10~9/L持续时间为(4.01±1.13)d,两组比较差异均无统计学意义(P>0.05)。观察组患者的不良反应发生率为13.33%,对照组患者的不良反应发生率为6.67%,两组比较差异无统计学意义(P>0.05)。结论:聚乙二醇化重组人粒细胞集落刺激因子一次给药在预防淋巴瘤化疗后粒细胞减少方面的效果与重组人粒细胞集落刺激因子多次给药比较更优,故更值得推广前一种方案。
Objective:To investigate the preventive effect of recombinant human granulocyte colonystimulating factor(pegf) on granulocytosis after chemotherapy of lymphoma.Method:54 cases of lymphoma chemotherapy patients were analyzed. They were randomly divided into two groups.The observation group was treated with pegylated recombinant human granulocyte colony-stimulating factor,and the control group was treated with recombinant human granulocyte colony-stimulating factor,30 cases in each group.Result:After treatment,the scores of quality of life and KPS in the observation group and the control group were significantly better than those before treatment(P<0.05).After treatment,the quality of life score and KPS score in the observation group were significantly better than those in the control group(P<0.05).The observation group of average minimum ANC value was(5.31±0.51)×10~9/L,ANC<2×109/L duration was(3.15±1.02)d,the average minimum ANC value in control group was(5.52±0.48)×109/L,ANC<2×10~9/L duration was(4.01±1.13)d,two groups were no significant difference in statistical significance(P>0.05).The incidence of adverse reactions in the observation group was 13.33%, and the incidence of adverse reactions in the control group was 6.67%,there was no significant difference between the two groups(P>0.05).Conclusion:Pegylated recombinant human granulocyte colony-stimulating factor is better than single recombinant human granulocyte colony-stimulating factor in preventing neutrophils after chemotherapy for lymphatic cancer,so it is worthy of promoting the former one.
Objective:To investigate the preventive effect of recombinant human granulocyte colonystimulating factor(pegf) on granulocytosis after chemotherapy of lymphoma.Method:54 cases of lymphoma chemotherapy patients were analyzed. They were randomly divided into two groups.The observation group was treated with pegylated recombinant human granulocyte colony-stimulating factor,and the control group was treated with recombinant human granulocyte colony-stimulating factor,30 cases in each group.Result:After treatment,the scores of quality of life and KPS in the observation group and the control group were significantly better than those before treatment(P<0.05).After treatment,the quality of life score and KPS score in the observation group were significantly better than those in the control group(P<0.05).The observation group of average minimum ANC value was(5.31±0.51)×10~9/L,ANC<2×109/L duration was(3.15±1.02)d,the average minimum ANC value in control group was(5.52±0.48)×109/L,ANC<2×10~9/L duration was(4.01±1.13)d,two groups were no significant difference in statistical significance(P>0.05).The incidence of adverse reactions in the observation group was 13.33%, and the incidence of adverse reactions in the control group was 6.67%,there was no significant difference between the two groups(P>0.05).Conclusion:Pegylated recombinant human granulocyte colony-stimulating factor is better than single recombinant human granulocyte colony-stimulating factor in preventing neutrophils after chemotherapy for lymphatic cancer,so it is worthy of promoting the former one.
引文
[1]张明,兰海涛,陈琳.聚乙二醇化重组人粒细胞集落刺激因子预防化疗后粒细胞减少方临床观察[J].中国新药杂志,2014,23(7):815-817.
[2]罗树春,胡洪林,吴琦.聚乙二醇化重组人粒细胞集落刺激因子预防化疗后粒细胞减少的临床观察[J].四川医学,2011,32(12):1879-1882.
[3]何小慧,周生余,董梅,等.聚乙二醇化重组人粒细胞集落刺激因子预防化疗后中性粒细胞减少的有效性分析[J].中国肿瘤临床,2015,14(12):626-631.
[4]Fujiwara A,Higashiyama M,Kanou T,et al.Granulocytecolony stimulating factor(G-CSF)producing malignant pleural mesothelioma:Report of a case[J].Thorac Cancer,2015,6(1):105-109.
[5]蔡艳霞,王晓燕,曾丽吟,等.阿糖胞苷、阿柔比星联合粒细胞集落刺激因子治疗骨髓增生异常综合征的临床研究[J].国际输血及血液学杂志,2015,38(1):28-32.
[6]高天,刘佳勇,方志伟,等.软组织肉瘤化疗聚乙二醇化重组人粒细胞集落刺激因子预防中性粒细胞减少临床观察[J].中华肿瘤防治杂志,2015,22(16):1313-1317.
[7]刘浩,任浩洋,孙纯广.重组人粒细胞集落刺激因子(rh GCSF)对小细胞肺癌化疗后骨髓抑制的有效性和安全性分析[J].中国临床药理学杂志,2009,12(6):278-279.
[8]邓小军,徐蜀远,杨丽萍.重组人粒细胞刺激因子临床应用安全性评价与合理用药[J].中国药业,2016,11(19):348-349.
[9]陈蓉,张晓静,何志旭.重组人粒细胞集落刺激因子对缺氧缺血性脑损伤新生大鼠脑组织Nogo受体表达的影响[J].中华实用儿科临床杂志,2015,30(6):129-130.
[10]邵珊,白海涛,王椿.聚乙二醇重组人粒细胞集落刺激因子在复发难治恶性淋巴瘤自体外周血造血干细胞动员中的应用研究[J].中国肿瘤临床,2017,22(13):737-738.
[11]Lteif A A,Han K,Mather K J.Obesity,Insulin Resistance,and the Metabolic Syndrome[J].Circulation,2013,112(1):32-38.
[12]马延超,李明,邢爽.细胞因子联合应用对重度骨髓型急性放射病猴的治疗作用研究[J].中国实验血液学杂志,2016,13(2):826-827.
[13]刘国建,陆彬彬,王朝霞.重组人粒细胞集落刺激因子混合液治疗化疗引起口腔溃疡的临床观察[J].临床肿瘤学杂志,2015,13(8):927-928.
[14]钟俐强,杨斯皓,雷开键.康复新联合rh G-CSF防治放射性口腔炎的临床观察[J].现代肿瘤医学,2014(8):433-434.
[15]石蓓,赵然尊,许官学.重组人粒细胞集落刺激因子对兔颈动脉粥样硬化球囊损伤后再内皮化和内膜增生的影响[J].中华心血管病杂志,2009,14(5):681-682.
[16]吴凤鹏,张明,王军.PEG-rh G-CSF对同期放化疗所致Ⅲ度粒细胞缺乏患者挽救性治疗的临床研究[J].河北医药,2014,10(22):925-926.
[17]余小挺,张琼,吕杰强.不同剂量重组人粒细胞集落刺激因子对晚期卵巢癌化疗后骨髓抑制继发感染的预防[J].中华医院感染学杂志,2014,23(17):222-223.
[18]陈玉林,杨长福,韦华军.重组人粒细胞刺激因子、重组人粒细胞巨噬细胞刺激因子对肿瘤患者化疗后升高白细胞、中性粒细胞效果的比较[J].吉林医学,2016,10(2):564-565.
[19]Zhang Y R,Li W J,Yan T W,et al.Early Detection of Lesions of Dorsal Artery of Foot in Patients with Type 2 Diabetes Mellitus by High-frequency Ultrasonography[J].Journal of Huazhong University of Science and Technology(Medical Sciences),2011,29(3):387-390.
[20]李艳红,曹海青.针刺配合rh G-CSF在GP方案治疗非小细胞肺癌过程中对粒细胞减少的影响[J].上海针灸杂志,2014,16(9):938-939.
[21]刘青,关嵩,曹峰.PEG-rh G-CSF对同步放化疗中性粒细胞缺乏挽救性治疗临床分析[J].中华肿瘤防治杂志,2017,12(7):574-575.
[22]王萌,马向娟,董玉君.rh G-CSF对健康供者T细胞CCR5表达的不同调控及其与急性移植物抗宿主病的相关性研究[J].中国实验血液学杂志,2013,18(4):641-642.
[2]罗树春,胡洪林,吴琦.聚乙二醇化重组人粒细胞集落刺激因子预防化疗后粒细胞减少的临床观察[J].四川医学,2011,32(12):1879-1882.
[3]何小慧,周生余,董梅,等.聚乙二醇化重组人粒细胞集落刺激因子预防化疗后中性粒细胞减少的有效性分析[J].中国肿瘤临床,2015,14(12):626-631.
[4]Fujiwara A,Higashiyama M,Kanou T,et al.Granulocytecolony stimulating factor(G-CSF)producing malignant pleural mesothelioma:Report of a case[J].Thorac Cancer,2015,6(1):105-109.
[5]蔡艳霞,王晓燕,曾丽吟,等.阿糖胞苷、阿柔比星联合粒细胞集落刺激因子治疗骨髓增生异常综合征的临床研究[J].国际输血及血液学杂志,2015,38(1):28-32.
[6]高天,刘佳勇,方志伟,等.软组织肉瘤化疗聚乙二醇化重组人粒细胞集落刺激因子预防中性粒细胞减少临床观察[J].中华肿瘤防治杂志,2015,22(16):1313-1317.
[7]刘浩,任浩洋,孙纯广.重组人粒细胞集落刺激因子(rh GCSF)对小细胞肺癌化疗后骨髓抑制的有效性和安全性分析[J].中国临床药理学杂志,2009,12(6):278-279.
[8]邓小军,徐蜀远,杨丽萍.重组人粒细胞刺激因子临床应用安全性评价与合理用药[J].中国药业,2016,11(19):348-349.
[9]陈蓉,张晓静,何志旭.重组人粒细胞集落刺激因子对缺氧缺血性脑损伤新生大鼠脑组织Nogo受体表达的影响[J].中华实用儿科临床杂志,2015,30(6):129-130.
[10]邵珊,白海涛,王椿.聚乙二醇重组人粒细胞集落刺激因子在复发难治恶性淋巴瘤自体外周血造血干细胞动员中的应用研究[J].中国肿瘤临床,2017,22(13):737-738.
[11]Lteif A A,Han K,Mather K J.Obesity,Insulin Resistance,and the Metabolic Syndrome[J].Circulation,2013,112(1):32-38.
[12]马延超,李明,邢爽.细胞因子联合应用对重度骨髓型急性放射病猴的治疗作用研究[J].中国实验血液学杂志,2016,13(2):826-827.
[13]刘国建,陆彬彬,王朝霞.重组人粒细胞集落刺激因子混合液治疗化疗引起口腔溃疡的临床观察[J].临床肿瘤学杂志,2015,13(8):927-928.
[14]钟俐强,杨斯皓,雷开键.康复新联合rh G-CSF防治放射性口腔炎的临床观察[J].现代肿瘤医学,2014(8):433-434.
[15]石蓓,赵然尊,许官学.重组人粒细胞集落刺激因子对兔颈动脉粥样硬化球囊损伤后再内皮化和内膜增生的影响[J].中华心血管病杂志,2009,14(5):681-682.
[16]吴凤鹏,张明,王军.PEG-rh G-CSF对同期放化疗所致Ⅲ度粒细胞缺乏患者挽救性治疗的临床研究[J].河北医药,2014,10(22):925-926.
[17]余小挺,张琼,吕杰强.不同剂量重组人粒细胞集落刺激因子对晚期卵巢癌化疗后骨髓抑制继发感染的预防[J].中华医院感染学杂志,2014,23(17):222-223.
[18]陈玉林,杨长福,韦华军.重组人粒细胞刺激因子、重组人粒细胞巨噬细胞刺激因子对肿瘤患者化疗后升高白细胞、中性粒细胞效果的比较[J].吉林医学,2016,10(2):564-565.
[19]Zhang Y R,Li W J,Yan T W,et al.Early Detection of Lesions of Dorsal Artery of Foot in Patients with Type 2 Diabetes Mellitus by High-frequency Ultrasonography[J].Journal of Huazhong University of Science and Technology(Medical Sciences),2011,29(3):387-390.
[20]李艳红,曹海青.针刺配合rh G-CSF在GP方案治疗非小细胞肺癌过程中对粒细胞减少的影响[J].上海针灸杂志,2014,16(9):938-939.
[21]刘青,关嵩,曹峰.PEG-rh G-CSF对同步放化疗中性粒细胞缺乏挽救性治疗临床分析[J].中华肿瘤防治杂志,2017,12(7):574-575.
[22]王萌,马向娟,董玉君.rh G-CSF对健康供者T细胞CCR5表达的不同调控及其与急性移植物抗宿主病的相关性研究[J].中国实验血液学杂志,2013,18(4):641-642.